ISTH Announces New Partnership with Elsevier to Publish the Society’s Two Scientific Journals, JTH and RPTH, Beginning January 2023
Chapel Hill, NC | September 13, 2022
The International Society on Thrombosis and Haemostasis (ISTH) announces a new partnership with Elsevier, a global leader in information and analytics, to publish its two scientific publications, the Journal of Thrombosis and Haemostasis (JTH) and Research and Practice in Thrombosis and Haemostasis (RPTH). The journals will be hosted on Elsevier’s leading online platform, ScienceDirect, beginning January 2023
“At the ISTH, we take great pride in our journals and our commitment to publish high quality and influential basic, translational, and clinical science to advance the understanding of thrombosis and hemostasis,” said Flora Peyvandi, M.D., Ph.D., ISTH President. “Our new partnership with Elsevier will allow us to further expand the depth of our journals with enhanced technology solutions that will positively impact services for authors and readers, which ultimately benefits patients.”
As the flagship journal of the ISTH and celebrating its 20th anniversary in 2023, JTH continues to be a leading resource in the field publishing high quality, original research reports, state of the art reviews, brief reports, case reports, invited commentaries and more. Its authors, reviewers and editors volunteer their time and expertise to contribute and disseminate important scientific information to the international research community with a hybrid subscription-based model.
In 2022, the JTH achieved a historically high impact factor of 16.036, ranked fifth overall in the hematology subject category and ranked third in the peripheral vascular disease category.
RPTH, celebrating its fifth anniversary in 2022, is an exclusive open-access and online-only publication dedicated to science and discourse among researchers, clinicians, nurses, allied health professionals, as well as patients. RPTH serves as a catalyst for global discussion and connects scientists and clinicians with the non-scientist public to discuss the latest findings and research in the field. In 2021, the journal was accepted into the Science Citation Index Expanded (SCIE) qualifying it to receive its first Impact Factor of 5.953 this year. RPTH also ranked 24th overall in the hematology subject category and ranked 16th in the peripheral vascular disease category.
“We are delighted that the ISTH has selected Elsevier as its publishing partner. By combining their expertise with Elsevier’s industry-leading resources for authors, editors, peer reviewers and readers, we will ensure the best possible support for ISTH’s mission and community. By working together, we can achieve a more inclusive, collaborative and transparent world of research,” stated Carl Schwarz Senior Vice President, Health and Medical Sciences, at Elsevier. “JTH and RPTH are highly respected journals in the field and are a great fit to the Elsevier hematology journal portfolio, we are extremely proud to work with ISTH and look forward to helping the society and their journals transition to Elsevier,” added Rachel Garland, Elsevier’s Publisher for Hematology. For more information on JTH and RPTH, visit https://www.isth.org/page/Publications(opens in new tab/window).
About the International Society on Thrombosis and Haemostasis (ISTH)
Founded in 1969, the ISTH(opens in new tab/window) is the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis, and treatment of conditions related to thrombosis and hemostasis. ISTH is an international medical-scientific professional membership organization with more than 7,500 clinicians, researchers, and educators working together to improve the lives of patients in more than 110 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, research activities, meetings and congresses, peer-reviewed publications, expert committees, and World Thrombosis Day on 13 October.
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses.
Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, medical education, and nursing education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet(opens in new tab/window) and Cell(opens in new tab/window); 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation(opens in new tab/window) and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier is part of RELX(opens in new tab/window), a global provider of information-based analytics and decision tools for professional and business customers.